GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (NAS:CVAC) » Definitions » Price-to-Free-Cash-Flow

CureVac NV (CureVac NV) Price-to-Free-Cash-Flow : N/A (As of May. 31, 2024)


View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Price-to-Free-Cash-Flow?

As of today (2024-05-31), CureVac NV's share price is $3.8899. CureVac NV's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.51. Hence, CureVac NV's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for CureVac NV's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 6 years, CureVac NV's highest Price-to-Free-Cash-Flow Ratio was 28.59. The lowest was 0.00. And the median was 0.00.

CVAC's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.41
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

CureVac NV's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.49. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.51.

During the past 6 years, CureVac NV's highest 3-Year average Free Cash Flow per Share Growth Rate was -50.30% per year. The lowest was -108.90% per year. And the median was -79.60% per year.


CureVac NV Price-to-Free-Cash-Flow Historical Data

The historical data trend for CureVac NV's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Price-to-Free-Cash-Flow Chart

CureVac NV Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - 18.54 - - -

CureVac NV Quarterly Data
Mar19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CureVac NV's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, CureVac NV's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CureVac NV's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where CureVac NV's Price-to-Free-Cash-Flow falls into.



CureVac NV Price-to-Free-Cash-Flow Calculation

CureVac NV's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=3.8899/-1.507
=N/A

CureVac NV's Share Price of today is $3.8899.
CureVac NV's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.51.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

CureVac NV  (NAS:CVAC) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


CureVac NV Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of CureVac NV's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


CureVac NV (CureVac NV) Business Description

Address
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.